☆ 4.7 Letter

Cancer bio-immunotherapy XVIII annual NIBIT-(Italian network for tumor biotherapy) meeting, October 15-16, 2020

CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)

Get Full Text
Add to Collection

Journal

CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 71, Issue 7, Pages 1787-1794

Publisher

SPRINGER
DOI: 10.1007/s00262-022-03145-0

Keywords

Immunotherapy; Cancer vaccines; Checkpoint blockade agents; Adoptive immunotherapy; Targeted therapies; NIBIT

Categories

Oncology Immunology

Funding

  1. AstraZeneca
  2. Becton Dikinson
  3. Bristol Meyers Squibb
  4. Diatech Labline
  5. Fuidigm
  6. Incyte
  7. Merck Sharp and Dome (MSD)
  8. Milteny Biotech
  9. Nano String
  10. Novartis
  11. Pierre Fabre Oncology
  12. Promega
  13. AIOM
  14. Associazione Italiana Oncologia Toracica (AIOT)
  15. Fondazione Associazione Italiana per la Ricerca sul Cancro (AIRC)
  16. ACC
  17. Fondazione Melanoma onlus
  18. Fondazione Grazia Focacci
  19. Istituto Oncologico Veneto (IOV)
  20. Fondazione Pezcoller
  21. SIC
  22. SIICA
  23. Women for Oncology Italy

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.